Trial Profile

A Phase 1, Open-label Study to Assess the Safety and Pharmacokinetics of SPR206 Following a Single IV Dose of SPR206 in Subjects With Varying Degrees of Renal Function

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPR-206 (Primary)
Indications Acinetobacter infections; Gram-negative infections
Focus Pharmacokinetics
Sponsors Spero Therapeutics

Most Recent Events

13 Mar 2024 According to a Spero Therapeutics media release, data from this study was published in Antimicrobials and Chemotherapy in October 2023.
14 Dec 2021 Status changed from recruiting to completed.
15 Jun 2021 According to a Spero Therapeutics media release, this study is being conducted in collaboration with, and with financial support from, the United States Department of Defense (Award No. W81XWH1910295).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com